The definitions for quality of evidence (strong, moderate, low, and very low) and strength of recommendations (strong or conditional) are provided at the end of the "Major Recommendations" field.
Definition and Causes of Esophageal Eosinophilia
- Esophageal eosinophilia, the finding of eosinophils in the squamous epithelium of the esophagus, is abnormal and the underlying cause should be identified (Recommendation strong, evidence moderate).
Definition of Eosinophilic Esophagitis (EoE) and Diagnostic Criteria
- EoE is a clinicopathologic disorder diagnosed by clinicians taking into consideration both clinical and pathologic information without either of these parameters interpreted in isolation, and defined by the following criteria:
- Symptoms related to esophageal dysfunction
- Eosinophil-predominant inflammation on esophageal biopsy, characteristically consisting of a peak value of ≥15 eosinophils per high-power field (eos/hpf)
- Mucosal eosinophilia is isolated to the esophagus and persists after a proton-pump inhibitor (PPI) trial
- Secondary causes of esophageal eosinophilia excluded (see Table 2 in the original guideline document)
- A response to treatment (dietary elimination; topical corticosteroids) supports, but is not required for, diagnosis (Strong recommendation, low evidence).
- Esophageal biopsies are required to diagnose EoE; 2–4 biopsies should be obtained from both the proximal and distal esophagus to maximize the likelihood of detecting esophageal eosinophilia in all patients in whom EoE is being considered (Recommendation strong, evidence low).
- At the time of initial diagnosis, biopsies should be obtained from the antrum and/or duodenum to rule out other causes of esophageal eosinophilia in all children and in adults with gastric or small intestinal symptoms or endoscopic abnormalities (Recommendation strong, evidence low).
Diagnostic Challenges: PPI-Responsive Esophageal Eosinophilia and Gastroesophageal Reflux Disease (GERD)
- Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) should be diagnosed when patients have esophageal symptoms and histologic findings of esophageal eosinophilia, but demonstrate symptomatic and histologic response to proton-pump inhibition. At this time, the entity is considered distinct from EoE, but not necessarily a manifestation of GERD (Recommendation conditional, evidence low).
- To exclude PPI-REE, patients with suspected EoE should be given a 2-month course of a PPI followed by endoscopy with biopsies (Recommendation strong, evidence low).
- A clinical, endoscopic and/or histologic response to a PPI does not establish gastroesophageal reflux as the cause of esophageal eosinophilia. To determine whether reflux is contributing to esophageal eosinophilia, additional evaluation for GERD, as per standard clinical practice, is recommended. This may include ambulatory pH testing in selected cases (Recommendation conditional, evidence low).
Endpoints of Treatment in EoE
- The endpoints of therapy of EoE include improvements in clinical symptoms and esophageal eosinophilic inflammation. While complete resolution of symptoms and pathology is an ideal endpoint, acceptance of a range of reductions in symptoms and histology is a more realistic and practical goal in clinical practice (Recommendation conditional, evidence low).
- Symptoms are an important parameter of response in EoE, but cannot be used alone as a reliable determinant of disease activity and response to therapy, given that compensatory dietary and lifestyle factors can mask symptoms (Recommendation conditional, evidence moderate).
- Topical steroids (i.e., fluticasone or budesonide, swallowed rather than inhaled, for an initial duration of 8 weeks) are a first-line pharmacologic therapy for treatment of EoE (Recommendation strong, evidence high).
- Prednisone may be useful to treat EoE if topical steroids are not effective or in patients who require rapid improvement in symptoms (Recommendation conditional, evidence low).
- Patients without symptomatic and histologic improvement after topical steroids might benefit from a longer course of topical steroids, higher doses of topical steroids, systemic steroids, elimination diet, or esophageal dilation (Recommendation conditional, evidence low). There are few data to support the use of mast cell stabilizers or leukotriene inhibitors, and biologic therapies remain experimental at this time.
- Dietary elimination can be considered as an initial therapy in the treatment of EoE in both children and adults (Strong recommendation, evidence moderate).
- The decision to use a specific dietary approach (elemental, empiric, or targeted elimination diet) should be tailored to individual patient needs and available resources (Recommendation conditional, evidence moderate).
- Clinical improvement and endoscopy with esophageal biopsy should be used to assess response to dietary treatment when food antigens are either being withdrawn from or reintroduced to the patient (Recommendation conditional, evidence low).
- Gastroenterologists should consider consultation with an allergist to identify and treat extraesophageal atopic conditions, assist with treatment of EoE, and to help guide elemental and elimination diets (Recommendation conditional, evidence low).
- Esophageal dilation, approached conservatively, may be used as an effective therapy in symptomatic patients with strictures that persist in spite of medical or dietary therapy (Recommendation conditional, evidence moderate).
- Patients should be well informed of the risks of esophageal dilation in EoE including post-dilation chest pain, which occurs in up to 75 % of patients, bleeding, and esophageal perforation (Recommendation conditional, evidence moderate).
Natural History of EoE
- While knowledge of the natural history of EoE is limited, patients should be counseled about the high likelihood of symptom recurrence after discontinuing treatment due to the chronic nature of this disease (Recommendation strong, moderate evidence).
- The overall goal of maintenance therapy is to minimize symptoms and prevent complications of EoE, preserve quality of life, with minimal long-term adverse effects of treatments (Recommendation conditional, evidence low).
- Maintenance therapy with topical steroids and/or dietary restriction should be considered for all patients, but particularly in those with severe dysphagia or food impaction, high-grade esophageal stricture and rapid symptomatic/histologic relapse following initial therapy (Recommendation conditional, evidence low).
Quality of Evidence Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) System
The quality of evidence was either strong (further research is unlikely to change confidence in the estimate), moderate (further research is likely to change confidence in the estimate), low (further research is very likely to change confidence in the estimate), or very low (the estimate of the effect is very uncertain).
Strength of Recommendations Using the Grade System
Recommendations were either strong (desirable effects outweigh undesirable effects) or conditional (trade-offs are less certain).
The original guideline document contains a clinical algorithm for the approach to esophageal eosinophilia (EoE) and diagnosis of EoE.
- Esophageal eosinophilia
- Eosinophilic esophagitis (EoE)
Allergy and Immunology
Advanced Practice Nurses
To provide recommendations for the evaluation and management of patients with esophageal eosinophilia and eosinophilic esophagitis (EoE)
Adults and children with esophageal eosinophilia and eosinophilic esophagitis (EoE)
- Assessment of signs and symptoms
- Esophageal biopsies
- Management of proton-pump inhibitor (PPI) responsive esophageal eosinophilia
- PPI for 2 months, followed by endoscopy with biopsies
- Assessment of symptom improvement
- Pharmacologic therapy
- Topical steroids (fluticasone/budesonide)
- Dietary treatments
- Elimination diet
- Consultation with allergist
- Identification and treatment of extra-esophageal atopic conditions
- Endoscopic treatment
- Esophageal dilation
- Maintenance therapy
- Topical steroids and/or dietary restriction
- Predictive/ prognostic value of diagnostic tests
- Efficacy of treatment
- Symptom control
- Adherence to treatment regimen
- Incidence of symptom recurrence after discontinuing treatment
- Quality of life
Searches of Electronic Databases
A search of PubMed and Ovid was performed using the search terms 'eosinophilic esophagitis', 'esophageal eosinophilia', 'ringed esophagus' and 'esophagus eosinophils' for years 1993 to present. There were no specific inclusion or exclusion criteria.
Weighting According to a Rating Scheme (Scheme Given)
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to evaluate the quality of supporting evidence. The quality of evidence was either strong (further research is unlikely to change confidence in the estimate), moderate (further research is likely to change confidence in the estimate), low (further research is very likely to change confidence in the estimate), or very low (the estimate of the effect is very uncertain).
Review of Published Meta-Analyses
See the "Rating Scheme for the Strength of the Evidence" field.
See the "Rating Scheme for the Strength of the Recommendations" field.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to grade the strength of recommendations. Recommendations were either strong (desirable effects outweigh undesirable effects) or conditional (trade-offs are less certain).
A cost analysis was not performed and published cost analyses were not reviewed.
Internal Peer Review
In an effort to make our new guidelines as "fresh" as possible when published, we have created a special guideline review process, involving members of the Board of Trustees, Practice Parameters Committee and the American Journal of Gastroenterology. It is our goal to review the guideline, allow you to revise the guideline, and re-review the guideline within 6 months of first submission. Therefore the entire process should take 1 year from commission to finished, accepted guideline.
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).
Appropriate diagnosis and management of patients with esophageal eosinophilia and eosinophilic esophagitis (EoE)
Risks of Esophageal Dilation
- Patients should be well informed of the risks of esophageal dilation in esophageal eosinophilia (EoE) including post-dilation chest pain, which occurs in up to 75 % of patients, bleeding, and esophageal perforation.
- In two recent meta-analyses of esophageal dilation in EoE, the perforation rate for dilation was 0.3 %, similar to that quoted for esophageal dilation for other benign esophageal diseases. It is important to note, however, that this rate was achieved at academic centers experienced in performing esophageal dilation in patients with EoE.
- The most common risk of dilation in EoE is post-procedural chest pain, reported in almost three quarters of patients when asked about this symptom prospectively. Major bleeding defined by need for endoscopic hemostasis or blood product is rare (only 1 patient reported to date).
The majority of recommendations in the original guideline document are "conditional" rather than "strong", further emphasizing the paucity of firm data guiding decisions and the likelihood of changing consensus in answer to even some of the most basic questions about this disease.
An implementation strategy was not provided.
|Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013 May;108(5):679-92. PubMed|
Not applicable: The guideline was not adapted from another source.
American College of Gastroenterology - Medical Specialty Society
American College of Gastroenterology
Authors: Evan S. Dellon, MD, MPH; Nirmala Gonsalves, MD; Ikuo Hirano, MD, FACG; Glenn T. Furuta, MD; Chris A. Liacouras, MD; David A. Katzka, MD, FACG
Evan S. Dellon has received grant/research funding from AstraZeneca, Meritage Pharma, American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), National Institutes of Health (NIH), Campaign Urging Research for Eosinophilic Disease (CURED) Foundation, and educational support from Pentax. Glenn T. Furuta has received grant/research support from Meritage Pharma, Nutricia and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. Ikuo Hirano has received grant/research funding from NIH and CURED Foundation. Nirmala Gonsalves has received grant/research funding from CURED Foundation.
Potential Competing Interests
David A. Katzka, Nirmala Gonsalves declare no conflict of interest. Evan S. Dellon is a consultant to Oncoscope. Christopher A. Liacouras is a speaker for Nutricia, and is on the American Partnership for Eosinophilic Disorders. Ikuo Hirano is on the advisory board of Meritage and Aptalis.
This is the current release of the guideline.
Available from the American College of Gastroenterology (ACG) Web site .
The following is available:
- American College of Gastroenterology Practice Parameters Committee. Guideline development policies. 2010 Jan. Available from the American College of Gastroenterology (ACG) Web site .
Information on eosinophilic esophagitis (EoE) is available on the American College of Gastroenterology's Patient Education & Resource Center Web site .
Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.
This NGC summary was completed by ECRI Institute on June 20, 2013. The information was verified by the guideline developer on June 25, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.